Bridging, switching or drug holidays - how to treat a patient who stops natalizumab? (Q38152451)

29 August 2017

Bridging, switching or drug holidays - how to treat a patient who stops natalizumab? (English)

1 reference

29 August 2017

Tania Kümpfel

1 reference

29 August 2017

Ingo Kleiter

1 reference

29 August 2017

Joachim Havla

1 reference

29 August 2017

3 October 2013

1 reference

Therapeutics and Clinical Risk Management

29 August 2017

1 reference

29 August 2017

1 reference

29 August 2017

361-369

1 reference

PMC publication ID

3794889

Creative Commons Attribution-NonCommercial 3.0 Unported

29 August 2017

start time

1 October 2013

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Alemtuzumab treatment of multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

BG-12 in multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Course of relapsing–remitting multiple sclerosis before, during and after natalizumab

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Early development of anti-natalizumab antibodies in MS patients

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Natalizumab therapy for multiple sclerosis

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Tumefactive multiple sclerosis lesions under fingolimod treatment

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Randomized trial of oral teriflunomide for relapsing multiple sclerosis

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Evolution of nevi during treatment with natalizumab: A prospective follow-up of patients treated with natalizumab for multiple sclerosis.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Anti-JC virus antibodies: implications for PML risk stratification

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Primary central nervous system lymphoma in a patient treated with natalizumab

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Melanoma complicating treatment with natalizumab for multiple sclerosis

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Immune surveillance in multiple sclerosis patients treated with natalizumab.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794889

Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: enigma, wrapped in mystery, enclosed in conundrum

31 August 2018

1 reference

12 December 2020

Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months

1 reference

12 December 2020

PML in a patient treated with fumaric acid

1 reference

12 December 2020

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab

1 reference

12 December 2020

Severe relapses under fingolimod treatment prescribed after natalizumab

1 reference

12 December 2020

Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse

1 reference

12 December 2020

Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance

1 reference

12 December 2020

Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?

1 reference

12 December 2020

PML in a patient treated with dimethyl fumarate from a compounding pharmacy

1 reference

12 December 2020

Hypereosinophilia in patients with multiple sclerosis treated with natalizumab

1 reference

12 December 2020

Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study

1 reference

12 December 2020

Lethal multiple sclerosis relapse after natalizumab withdrawal

1 reference

12 December 2020

Natalizumab-associated complication? First case of peripheral T cell lymphoma

1 reference

12 December 2020

Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy

1 reference

12 December 2020

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

12 December 2020

Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients

1 reference

12 December 2020

More on melanoma with transdifferentiation

1 reference

12 December 2020

Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study

1 reference

12 December 2020

Manufacturer's response to case reports of PML

1 reference

12 December 2020

Identifiers

DOI

10.2147/TCRM.S41552

1 reference

29 August 2017

1 reference

PMC publication ID

3794889

29 August 2017

PubMed publication ID

24124371

1 reference

PMC publication ID

3794889